Biomerica (NASDAQ:BMRA) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $1.26 million which missed the analyst consensus estimate of $2.05 million by 38.44 percent. This is a 10.31 percent increase over sales of $1.14 million the same period last year.
Related Posts
Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
Novartis AG (NYSE:NVS) has reported Q4 core EPS of $1.52 compared to $1.40 a year ago, beating the consensus of $1.44.…
ThermoGenesis Reported in Filing Tuesday It Received a Conversion Notice From Boyalife Asset Holding II to Convert a Total of $3M of the Outstanding Balance of the Second Amended and Restated Convertible Promissory Note Issued to Boyalife on April 16,…
On June 28, 2022, ThermoGenesis Holdings, Inc. (the "Company") received a conversion notice from Boyalife Asset Holding II, Inc.("Boyalife") to convert a total of $3,000,000 of the outstanding balance of the Second Amended and Restated Convertible Promissory Note issued by the Company to Boyalife on April 16, 2018, as amended by Amendment No 1 thereto dated March 4, 2022 (as amended, the "Note").
Nike Sees Strong Demand, But Supply Hurdles Hurt Guidance: Analyst
Nike Inc (NYSE: NKE) reported mixed results for the first fiscal quarter of 2022, with earnings ahead of the consensus estimates on revenues that missed expectations, accord